TY - JOUR
T1 - ‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure
AU - APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party
AU - Choudhury, Ashok
AU - Vijayaraghavan, Rajan
AU - Maiwall, Rakhi
AU - Kumar, Manoj
AU - Duan, Zhongping
AU - Yu, Chen
AU - Hamid, Saeed Sadiq
AU - Jafri, Wasim
AU - Butt, Amna Subhan
AU - Devarbhavi, Harshad
AU - Ning, Qin
AU - Ma, Ke
AU - Tan, Soek Siam
AU - Shukla, Akash
AU - Dhiman, Radhakrishna
AU - Duseja, Ajay
AU - Taneja, Sunil
AU - Eapen, C. E.
AU - Goel, Ashish
AU - Treeprasertsuk, Sombat
AU - Al-Mahtab, Mamun
AU - Ghazinyan, Hasmik
AU - Kim, Dong Joon
AU - Sahu, Manoj K.
AU - Lee, Guan Huei
AU - Lesmana, Laurentius A.
AU - Lesmana, Rinaldi Cosmas
AU - Shah, Samir
AU - Abbas, Zaigham
AU - Sollano, Jose D.
AU - Rao, P. N.
AU - Kulkarni, Anand
AU - Shiha, Gamal
AU - Shrestha, Ananta
AU - Dokmeci, AKadir K.
AU - Yuen, Man Fung
AU - Payawal, Diana Alcantara
AU - Kalista, Kemal Fariz
AU - Prasad, V. G.Mohan
AU - Lau, George K.
AU - Karim, Fazal
AU - Jain, Priyanka
AU - Kumar, Guresh
AU - Arora, Vinod
AU - Pamecha, Viniyendra
AU - Sinha, Piyush
AU - Sarin, Shiv K.
N1 - Funding Information:
The project under the APASL ACLF working party with a research grant from APASL as a project to APASL ACLF Research Consortium (AARC).
Publisher Copyright:
© 2021, Asian Pacific Association for the Study of the Liver.
PY - 2021/12
Y1 - 2021/12
N2 - Background and aims: Acute-on-chronic liver failure (ACLF) is a rapidly progressive illness with high short-term mortality. Timely liver transplant (LT) may improve survival. We evaluated various indices for assessment of the severity of liver failure and their application for eligibility and timing of living donor LT (LDLT). Methods: Altogether 1021 patients were analyzed for the severity and organ failure at admission to determine transplant eligibility and 28 day survival with or without transplant. Results: The ACLF cohort [mean age 44 ± 12.2 years, males 81%) was of sick patients; 55% willing for LT at admission, though 63% of them were ineligible due to sepsis or organ failure. On day 4, recovery in sepsis and/or organ failure led to an improvement in transplant eligibility from 37% at baseline to 63.7%. Delay in LT up to 7 days led to a higher incidence of multiorgan failure (p < 0.01) contributing to 23% of the first week and 55% of all-cause 28-day mortality. In a matched cohort analysis, the actuarial survival with LT (n = 41) and conditional survival in the absence of transplant (n = 191) were comparable, when the condition, i.e., transplant was adjusted. The comparison curve showed differentiation in survival beyond 7 days (p < 0.01). Conclusions: ACLF is a rapidly progressive disease and risk stratification within the first week of hospitalization is needed. ‘Emergent LT’ should be defined in the first week in the ACLF patients; the transplant window for improving survival in a live donor setting. Graphic abstract: [Figure not available: see fulltext.]
AB - Background and aims: Acute-on-chronic liver failure (ACLF) is a rapidly progressive illness with high short-term mortality. Timely liver transplant (LT) may improve survival. We evaluated various indices for assessment of the severity of liver failure and their application for eligibility and timing of living donor LT (LDLT). Methods: Altogether 1021 patients were analyzed for the severity and organ failure at admission to determine transplant eligibility and 28 day survival with or without transplant. Results: The ACLF cohort [mean age 44 ± 12.2 years, males 81%) was of sick patients; 55% willing for LT at admission, though 63% of them were ineligible due to sepsis or organ failure. On day 4, recovery in sepsis and/or organ failure led to an improvement in transplant eligibility from 37% at baseline to 63.7%. Delay in LT up to 7 days led to a higher incidence of multiorgan failure (p < 0.01) contributing to 23% of the first week and 55% of all-cause 28-day mortality. In a matched cohort analysis, the actuarial survival with LT (n = 41) and conditional survival in the absence of transplant (n = 191) were comparable, when the condition, i.e., transplant was adjusted. The comparison curve showed differentiation in survival beyond 7 days (p < 0.01). Conclusions: ACLF is a rapidly progressive disease and risk stratification within the first week of hospitalization is needed. ‘Emergent LT’ should be defined in the first week in the ACLF patients; the transplant window for improving survival in a live donor setting. Graphic abstract: [Figure not available: see fulltext.]
KW - ACLF
KW - Liver transplant
KW - Transplant window
UR - http://www.scopus.com/inward/record.url?scp=85116835370&partnerID=8YFLogxK
U2 - 10.1007/s12072-021-10206-6
DO - 10.1007/s12072-021-10206-6
M3 - Article
C2 - 34608586
AN - SCOPUS:85116835370
SN - 1936-0533
VL - 15
SP - 1376
EP - 1388
JO - Hepatology International
JF - Hepatology International
IS - 6
ER -